The association between Helicobacter pylori infection and inflammatory bowel disease based on meta‐analysis

Rokkas, Theodore; Gisbert, J.P.; Niv, Yaron; O’Moráin, Colm

doi:10.1177/2050640615580889

Cited by 88 publications

(120 citation statements)

References 71 publications

(108 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…However, findings are varied and, to date, have failed to support a definitive association in IBD (Hold et al, 2014). A recent meta-analysis involving 33 studies that included 4400 IBD patients showed a significant negative association between H. pylori and IBD (Rokkas et al, 2015). Furthermore, a recent cohort study indicated that the organism might be protective against CD development (Bartels et al, 2016).…”

Section: Helicobacter Speciesmentioning

confidence: 99%

An overview of the bacterial contribution to Crohn disease pathogenesis

Alhagamhmad

Day

Lemberg

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

Section: Helicobacter Speciesmentioning

confidence: 99%

An overview of the bacterial contribution to Crohn disease pathogenesis

Alhagamhmad

Day

Lemberg

et al. 2016

Journal of Medical Microbiology

View full text Add to dashboard Cite

“…A more recent meta-analysis of 33 eligible studies that included 4,400 IBD patients and 4,763 controls (the vast majority being non-Asian) found that 26.5% of IBD patients were H. pylori positive, compared to 44.7% of individuals in the control group. These data resulted in an estimated risk ratio of 0.62 (95% confidence interval: 0.55-0.71, p < 0.001) [76]. In the most recent and most comprehensive meta-analysis to date (which includes studies published until July 2015), with data from 40 studies, CD and UC patients were evaluated together as well as separately [74].…”

Section: Epidemiological Evidence Suggests An Inverse Association Betmentioning

confidence: 99%

Helicobacter pylori: Does Gastritis Prevent Colitis?

Arnold¹,

Müller²

2016

Inflamm Intest Dis

View full text Add to dashboard Cite

Background: Since its discovery in the early 1980s, Helicobacter pylori has been linked to a variety of gastric and extragastric diseases. Chronic infection with H. pylori causes histologically evident gastritis in all colonized individuals and is the predominant risk factor for gastric and duodenal ulcers as well as gastric adenocarcinoma. However, increasingly robust experimental and epidemiological evidence suggests that H. pylori may at the same time be beneficial to its carriers, as it efficiently prevents allergic disorders and chronic inflammatory conditions. The purpose of this review is to summarize and document the latest evidence for a possible inverse association of H. pylori infection status and the risk of inflammatory bowel disease (IBD), as provided in both experimental and human observational studies. The pathogenesis of IBDs, the available mouse models for these diseases and the dual role of H. pylori in health and disease are presented in dedicated chapters. Summary and Key Messages: Almost all available epidemiological data suggest that H. pylori infection is inversely associated with both Crohn's disease (CD) and ulcerative colitis in European, Asian as well as American populations; large meta-analyses reviewing 30 original articles or more document that this inverse association is especially strong in CD patients and in children and young adults. Experimental data available from various mouse models of IBD confirm that live H. pylori infection as well as treatment with immunomodulatory molecules of H. pylori reduce clinical and histopathological IBD symptoms. Various proposed mechanisms involving the tolerization of dendritic cells, the production of protective cytokines and the preferential induction and differentiation of regulatory T-cells are presented. The implications of the beneficial aspects of the Helicobacter-host interaction for H. pylori eradication decisions, as well as potential new therapeutic options in the treatment of IBD are discussed in this review.

show abstract

“…The compound is ready for the phase III clinical trial. Probiotics and prebiotics may also be included in the treatment so as to normalize the GI microfloral ecosystem [14][15][16][17][18] .…”

Section: Current Treatments Of Gastrointestinal Diseasesmentioning

confidence: 99%

“…The infecting bacteria, or the antibiotics used to eliminate them, may also alter the balance of the indigenous microbiota. Often these problems are overcome on their own with time, but sometimes probiotic supplementation may be needed [10,[14][15][16][17][18] .…”

Section: Microbiota and Gastrointestinal Diseasesmentioning

confidence: 99%

“…Food poisoning may be viral, but is mostly due to bacterial contamination in food and water. A large portion of the population also has Helicobacter pylori infection, which can lead to secondary diseases [10,14,15] . The infecting bacteria, or the antibiotics used to eliminate them, may also alter the balance of the indigenous microbiota.…”

Section: Microbiota and Gastrointestinal Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

2017

View full text Add to dashboard Cite

The gastrointestinal tract digests and absorbs dietary nutrients, protects the body against physical and chemical damage from contents in its lumen, provides immunity against external antigens, and keeps an optimum environment for the gut microbiota. These functions cannot be performed normally in several diseases of which the following are discussed here: irritable bowel syndrome and inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Because these diseases are associated with oxidative stress, a host of antioxidant supplements are used for maintenance and recovery of the gut functions. However, the benefits of these supplements have not been established. The available 80 human trials were rated for levels of confidence and for benefits of the antioxidant supplements. For Crohn's disease, the supplements for which clear benefits occurred in at least 2 studies were allopurinol, Boswellia serrata (frankincense or shallaki), Artemesia species (wormwood), Tripterygium wilfordii (léi gōng téng), and omega-3 fatty acids. Similar beneficial supplements for ulcerative colitis were allopurinol, Matricaria chamomilla (chamomile), Curcuma longa (curcumin in turmeric), and omega-3 fatty acids. There was also a clear benefit for ulcerative colitis in 2 studies where a multiherbal Chinese medicine preparation and an Ayurvedic medicine preparation were used. For irritable bowel syndrome, there was only a marginal benefit of some of the antioxidant supplements. Thus, some antioxidant supplements may be beneficial at certain stages of specific diseases. This is consistent with the current concept that antioxidants act by inhibiting oxidative stress pathways in a tissue- and environment-specific manner and not by simply acting as scavengers.

show abstract

The association between Helicobacter pylori infection and inflammatory bowel disease based on meta‐analysis

Abstract: The results of this meta-analysis showed a significant negative association between H. pylori infection and IBD that supports a possible protective benefit of H. pylori infection against the development of IBD.

Cited by 88 publications

References 71 publications

An overview of the bacterial contribution to Crohn disease pathogenesis

An overview of the bacterial contribution to Crohn disease pathogenesis

<b><i>Helicobacter pylori</i></b>: Does Gastritis Prevent Colitis?

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

Contact Info

Product

Resources

About